A phase 1 clinical trial of IM-3050
Latest Information Update: 24 Sep 2025
At a glance
- Drugs IM 3050 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 06 Aug 2025 According to an Immunome media release, company received IND clearance for IM-3050 in April 2025 and expects to initiate a Phase 1 clinical trial before the end of 2025.
- 12 May 2025 According to the Immunome Media Release, received IND clearance for IM-3050 in April 2025.
- 25 Mar 2025 New trial record